Insilico Reports Promising Topline Results from Two Phase 1 Trials of ISM5411, an AI-Designed Therapy for Inflammatory Bowel Disease
Insilico Medicine, a trailblazer in the realm of artificial intelligence (AI)-driven drug discovery, has announced promising outcomes from two Phase I clinical trials of ISM5411,...